Universe Pharmaceuticals Files 6-K Report

Ticker: UPC · Form: 6-K · Filed: Feb 11, 2025 · CIK: 1809616

Universe Pharmaceuticals INC 6-K Filing Summary
FieldDetail
CompanyUniverse Pharmaceuticals INC (UPC)
Form Type6-K
Filed DateFeb 11, 2025
Risk Levellow
Pages2
Reading Time2 min
Sentimentneutral

Sentiment: neutral

Topics: 6-K, foreign-private-issuer, compliance

TL;DR

Universe Pharma (UPC) filed a 6-K, standard foreign issuer report. No major news.

AI Summary

Universe Pharmaceuticals INC, incorporated in the Cayman Islands, filed a Form 6-K on February 11, 2025. The filing is a report of a foreign private issuer for the month of February 2025. The company's principal executive offices are located at 265 Jingjiu Avenue, Jinggangshan Economic and Technological Development Zone, Ji'an, Jiangxi, China.

Why It Matters

This filing indicates ongoing reporting compliance for Universe Pharmaceuticals INC as a foreign private issuer, providing routine updates to the SEC.

Risk Assessment

Risk Level: low — The filing is a routine report of a foreign private issuer and does not contain material new information or financial disclosures.

Key Players & Entities

FAQ

What type of filing is this?

This is a Form 6-K, a Report of Foreign Private Issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934.

What period does this report cover?

The report is for the month of February 2025.

Where is Universe Pharmaceuticals INC headquartered?

The company's principal executive offices are located at 265 Jingjiu Avenue, Jinggangshan Economic and Technological Development Zone, Ji'an, Jiangxi, China.

Under which laws is Universe Pharmaceuticals INC incorporated?

Universe Pharmaceuticals INC is an exempted company incorporated under the laws of the Cayman Islands.

Does Universe Pharmaceuticals INC file annual reports under Form 20-F or 40-F?

The registrant indicates it files annual reports under cover of Form 20-F.

Filing Stats: 585 words · 2 min read · ~2 pages · Grade level 20 · Accepted 2025-02-11 16:10:07

Filing Documents

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities and Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.   Universe Pharmaceuticals INC Date: February 11, 2025   By:   /s/ Gang Lai         Gang Lai         Chief Executive Officer 2

View Full Filing

View this 6-K filing on SEC EDGAR

View on Read The Filing